Video
A record year for deal making in healthcare left many executives wondering whether they should broaden their companies' portfolios or deepen their penetration of a product category. In the end, pharmaceutical and medical technology companies and private equity owners with assets in these industries have more to gain from pursuing category leadership, whether by acquiring assets that expand a company's market share within a category or by divesting non-core businesses, says Nirad Jain, a partner with Bain's Healthcare and Private Equity practices, in this short video.
Read the report: Global Healthcare Private Equity Report 2015
First published in Απρίλιος 2015